V
Vigilant Biosciences
Vigilant Biosciences | Transforming Detection To Improve Outcomes
About Vigilant Biosciences
Vigilant Biosciences, established in 2011, is a medical technology firm centered on the development of solutions for the early detection of cancer. The company was founded by Matthew H.J. Kim, who was reportedly inspired by his parents' experiences with cancer. Since its inception, the company has progressed through several funding stages, securing approximately $29.8 million over five rounds, including a significant Series B round. Key investors include the Florida Institute, venVelo, and White Owl Capital Partners. A notable achievement for the company was receiving the FDA's Breakthrough Device Designation in March 2023 for its flagship product, a step that expedites the development and review process for novel medical devices.
The firm operates in the oncology and diagnostic equipment market, providing tools for healthcare professionals, particularly those in dentistry, to aid in the early identification of oral and oropharyngeal cancer. Its business model revolves around the sale of its diagnostic systems and associated tests to clinicians and healthcare providers. While the company's products are available in select international markets under CE Mark approval, they are not yet for sale in the United States, pending further regulatory clearance. The company has established a CLIA-certified laboratory, OncAlert Labs, to process tests in the U.S. market once approved.
Vigilant Biosciences' primary offering is the BeVigilant™ OraFusion System. This point-of-care system is designed to identify patients at risk for oral cancer through a non-invasive oral rinse. The technology works by measuring specific tumor-initiating and stem cell-associated biomarkers—specifically soluble CD44 and total protein levels—which are clinically associated with the presence of oral cancer, sometimes before visible symptoms appear. The system provides results in approximately 15 minutes during a patient's visit. It targets high-risk populations, including tobacco users, those with excessive alcohol consumption, and individuals with HPV-16. The OraFusion test uniquely combines biomarker detection with artificial intelligence software that considers clinical risk factors to assess a patient's risk.
Source: Dealroom company dataNews
Open roles
Vigilant Biosciences in the Lakeway ecosystem
The Vigilant Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A1 investor entered at this stage
venVelo
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vigilant Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vigilant Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
